Journal of Capital Medical University

Previous Articles     Next Articles

Real-world observation and safety analysis of belimumab combined with traditional regimen in the treatment of proliferative lupus nephritis

Wei Yang1,2, Zhao Shujuan1,3, Li Yi4, Yu Xiaoyong5, Cui Chenkai1,3, Yang Yuhan1,3, Ge Heng1,3, Gao Yi6, Mukiza Mwebembezi Ngemera1,3,7, Guo Bohui4, Cao Suilin8, Yuan Jianghong2, Xu Jing1,3, Fu Rongguo1,3*, Jia Ting1,3*   

  1. Department of Nephrology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China;2. Department of Nephrology, People's Hospital of Tongchuan, Tongchuan 727100, Shaanxi Province,China; 3. International Joint Research Center for Urinary System Injury and Repair, Xi'an 710004, China; 4. Department of Nephrology, Hanzhong 3201 Hospital, Hanzhong 723100, Shaanxi Province,China; 5. Department of Nephrology, Shaanxi Chinese Hospital, Xi'an 710004, China; 6. Department of Nephrology, The Affiliated Hospital of Northwest University, Xi'an No.3 Hospital, Xi'an 710004, China; 7. Kairuki Hospital of Dar es Salaam, Dar es Salaam 14112, Tanzania; 8. Department of Nephrology, Xi'an Gaoxin Hospital, Xi'an 710004, China
  • Received:2026-03-17 Online:2026-10-26 Published:2026-10-26
  • Supported by:
    This study was supported by  National Natural Science Foundation of China(82170697,82400821)。

Abstract: Objective  To compare the utilization rate, efficacy, and safety of belimumab combined with either glucocorticoid plus cyclophosphamide or glucocorticoid plus mycophenolate mofetil (MMF) traditional therapy in patients with proliferative (lupus nephritis, LN) in Shaanxi Province, China. Methods  A telephone survey was conducted to assess the distribution of nephrology specialty clinics and belimumab usage across Shaanxi province. Five hospitals at different levels and geographic locations were enrolled. The study included 109 adult patients (≥18 years old) diagnosed with class Ⅲ and/or Ⅳ ± V LN by renal biopsy. Based on inclusion and exclusion criteria, participants were divided into a traditional therapy group (n=20) and a belimumab combination group (n=26). General patient data and clinical parameters before and after treatment were collected. Belimumab usage rates were recorded. Renal response was categorized as complete remission, partial remission, or no renal response based on changes in proteinuria and renal function. Results  In Shaanxi province, 225 hospitals had hemodialysis centers and 82 had independent nephrology departments, of the latter 15 (18.3%) used belimumab. During treatment, no statistically significant difference was found in overall renal response between the two groups (P>0.05); however, the complete remission rates in the belimumab combination group at weeks 24, 48, and 108 were 57.69% (15/26), 92.31% (24/26), and 80.77% (21/26), respectively, consistently higher than those in the traditional therapy group [45.00% (9/20), 90.00% (18/20), and 70.00% (14/20)]. At week 108, four patients (20.0%) in the traditional therapy group experienced relapse, whereas none did in the belimumab combination group. Generalized estimating equation (GEE) analysis showed that, after log transformation and adjustment for baseline factors, the prednisone dosage in the belimumab combination group was significantly lower than that in the traditional therapy group [β=-0.424, exp(β)=0.655, 95%CI: 0.505-0.849, P=0.001]. Regarding safety, all patients in the belimumab combination group tolerated the infusions well without allergic reactions. Infections occurred in 8 patients (40.0%) in the traditional therapy group and 6 (23.1%) in the belimumab combination group; 2 patients in each group developed tumors during maintenance therapy. Conclusion  Combining belimumab with traditional therapy effectively alleviates proliferative LN and reduces glucocorticoid requirements. Belimumab infusion was well tolerated, nevertheless, vigilance is still needed for post-infusion infections and malignancies.

Key words: belimumab, lupus nephritis, glucocorticoid, mycophenolate mofetil, cyclophosphamide, sulfamethoxazole

CLC Number: